Chemotherapy At Home Services Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Chemotherapy At Home Services Market Trends and Insights

Rising Cancer Incidence and Treatment Volumes

The chemotherapy at home services market is gaining a larger patient base because global cancer volumes remain high and are still increasing.^{[1]World Health Organization, “Global Cancer Burden Growing, Amidst Mounting Need for Services,” World Health Organization, who.int} The World Health Organization reported 20 million new cancer cases and 9.7 million deaths in 2022, and it expects annual new cases to rise above 35 million by 2050. This rise matters for home-based care because hospital infusion capacity does not expand as quickly as case volumes in many health systems. The same pressure is being amplified by the large survivorship pool, with 53.5 million people alive within 5 years of a cancer diagnosis as of 2022. Many of these patients remain on adjuvant, maintenance, or repeat-cycle treatment plans that fit recurring home service models. That gives the chemotherapy at home services market a steady demand base that is not tied only to new diagnoses in a single year.

Preference Shift From Facility-Based Care to Home-Based Oncology Delivery

The chemotherapy at home services market is moving forward as providers, patients, and payers become more comfortable with treatment outside the hospital. Mayo Clinic’s Cancer CARE Beyond Walls program reported 93 home intravenous chemotherapy infusions with no infusion reactions and no catheter-related infections, which supports confidence in care quality and delivery safety.^{[2]R. Dronca et al., “Cancer CARE Beyond Walls, Safety, Feasibility, and Patient Experience of Home-Based Chemotherapy,” NEJM Catalyst, catalyst.nejm.org} The economic case is also strong, as UnitedHealth Group estimated that shifting cancer drug administration from hospital outpatient settings to home or physician office settings can reduce costs by 32%-39% per commercially insured patient. The same analysis estimated USD 12 billion in annual savings if the hospital infusion share drops from 60% to 30%. Those savings are encouraging payers to favor lower-cost settings more actively than before. As a result, the chemotherapy at home services market is being shaped not only by patient convenience, but also by deliberate site-of-care redirection.

Expansion of Remote Monitoring and Tele-Oncology Support Models

The chemotherapy at home services market is becoming easier to scale because remote monitoring is improving how providers supervise patients between visits. Digital home-based monitoring models are being used to track side effects during breast cancer therapy and support clinical decisions without requiring constant in-person review. These tools help care teams decide when a patient can continue treatment at home and when escalation is needed. They also reduce unnecessary routine interactions because nurse visits can be triggered by symptom alerts instead of fixed schedules. This matters most for oral and lower-acuity regimens, where safety depends more on fast visibility into symptoms than on continuous physical presence. That shifts the chemotherapy at home services market toward more selective, data-supported home eligibility rather than simple geographic proximity to an infusion site.

Home Infusion Logistics and Nurse Dispatch Networks Improving Treatment Feasibility

The chemotherapy at home services market depends heavily on logistics, because safe delivery requires pharmacy coordination, cold-chain movement, nurse dispatch, and dependable scheduling. Option Care Health reported more than 5,000 clinicians, more than 190 locations, and service coverage for over 315,000 patients annually across all 50 U.S. states, which shows the scale needed to manage complex home infusion demand.^{[3]Option Care Health, “Annual Report 2025,” U.S. Securities and Exchange Commission, sec.gov} Larger networks can absorb referral shifts more effectively because they already have staff, dispatch systems, and compounding links in place. They can also support broader payer relationships, which improves consistency in patient intake and authorization handling. Logistics depth becomes even more important when treatment requires multi-day ambulatory infusion or hazardous drug handling. For that reason, the chemotherapy at home services market is favoring operators with wide service footprints and more standardized operating models.

Oncology Nurse and Pharmacist Capacity Gaps

The chemotherapy at home services market faces a basic supply problem because oncology-trained nurses and pharmacists remain hard to recruit and retain. The Lancet Oncology Commission identified the global cancer workforce as a critical resource gap and linked care quality directly to staffing levels across countries and care settings. Home administration adds another layer of difficulty because general home health capabilities are not always enough for chemotherapy toxicity assessment and rapid response. Staff must distinguish treatment side effects from disease progression and make correct escalation decisions during visits or remote review. That raises training needs well above standard infusion support in lower-acuity services. Until that workforce base deepens, the chemotherapy at home services market will continue to expand more slowly than patient demand would otherwise allow.

Reimbursement Variability and Payer Authorization Friction

The chemotherapy at home services market also faces uneven financial support, which makes providers cautious about expanding programs too quickly. ASCO noted that the U.S. Acute Hospital Care at Home waiver, which supports hospital-at-home models under expanded Medicare rules, did not have permanent authorization in 2025. That uncertainty matters because investment in oncology-at-home capacity requires confidence that reimbursement pathways will remain stable over several years. A peer-reviewed Belgian study found that home hospitalization in oncology costs more than standard hospital-based care and that insurer reimbursement did not fully cover operating costs. When that gap appears, providers face margin pressure even if patient acceptance and clinical feasibility are both strong. This keeps the chemotherapy at home services market from moving at the same speed as the underlying clinical and cost case.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Drug Volume Dominates but Pump Economics Accelerate

Chemotherapy drugs held 61.31% of revenue in 2025 in the chemotherapy at home services market, which kept the revenue profile centered on drug spending rather than equipment or logistics fees. That position reflects how most patient episodes are still built around the therapy itself, with devices and home support layered around it. Multi-day intravenous regimens such as fluorouracil-based treatment for colorectal cancer reinforce this structure because the drug and the delivery setup are used together in a single care cycle. The pump segment is still the fastest-growing product category, with an 8.36% CAGR projected through 2031. That growth is coming from broader use cases rather than from a decline in drug importance. The chemotherapy at home services industry still depends on drugs as the primary billing driver, but devices are becoming more important for enabling a larger share of those therapies to move out of clinics.

Pump adoption is rising because product formats are widening, and providers can choose between lower-cost elastomeric systems and more connected smart platforms. Fresenius described its Ivenix smart infusion platform as a meaningful growth driver for 2026, and it highlighted advanced connectivity and a 97% drug library compliance rate in its investor communication. KORU Medical also moved to widen home eligibility when it submitted a 510(k) notification in January 2026 for the FreedomEDGE infusion system to administer pertuzumab, trastuzumab, and hyaluronidase subcutaneously at home for HER2-positive breast cancer. Medicare coverage support also improved, as the CMS LCD revision effective January 25, 2026 confirmed home coverage for ambulatory infusion pumps used with continuous antineoplastic drugs including fluorouracil, cytarabine, and vincristine. These changes are pushing the chemotherapy at home services market toward a larger installed pump base without changing the central role of chemotherapy drugs in total revenue.

By Route of Administration: IV Infrastructure Sustains Leadership While Oral Gains Strategic Relevance

Intravenous administration retained 82.68% of route revenue in 2025 and is projected to grow at a 9.74% CAGR through 2031 in the chemotherapy at home services market. This means the largest route is also the fastest-growing route, which reflects the scale of existing IV-dependent regimens and better home delivery support. Improved drug stability protocols and the spread of ambulatory pump platforms have made more IV treatment cycles practical outside hospitals. A 2024 patient satisfaction study in colorectal cancer found higher daytime and outdoor use satisfaction with soft-shelled elastomeric pumps, which supports continued preference for portable IV delivery formats in suitable regimens. These factors keep IV treatment central to the chemotherapy at home services market share even as care settings change. They also explain why route diversification is happening through home delivery models rather than through a rapid fall in IV use.

Oral chemotherapy still represented a smaller route base in 2025, but its strategic role is increasing because it removes the need for pump setup and routine nurse administration. Remote monitoring programs are becoming the main clinical oversight tool for these therapies, especially when treatment can be paired with side-effect tracking and direct patient reporting. The FDA approved Inqovi plus venetoclax in May 2026 as the first all-oral acute myeloid leukemia regimen for adults aged 75 years and older or for patients unable to tolerate intensive induction chemotherapy. BeOne Medicines also received FDA approval in June 2025 for a tablet formulation of BRUKINSA for all approved indications, which expanded portable oral treatment options in blood cancers. These approvals do not displace IV volume in the near term, but they widen the path for selected patients to receive full treatment courses at home with lighter infrastructure needs.

By Cancer Type: Breast Cancer's Volume Base Versus Blood Cancer's Momentum

Breast cancer accounted for 39.16% of revenue in 2025 in the chemotherapy at home services market, which made it the largest cancer type by service use. Its position reflects both high diagnosis volume and the broader set of regimens that can be managed safely in the home setting for selected patients. Global cancer statistics for 2022 continued to show breast cancer among the highest-incidence malignancies, which supports a large and recurring treatment base for home-compatible programs. Home eligibility in breast cancer is also widening because subcutaneous biologic formats are expanding beyond conventional clinic delivery. KORU Medical’s January 2026 filing for home subcutaneous delivery of Phesgo is a clear example of this shift toward easier home administration pathways.

Blood cancer is the fastest-growing indication, with a 8.99% CAGR projected through 2031 in the chemotherapy at home services market. Its growth pattern is different because it relies more on oral and subcutaneous innovation than on traditional ambulatory infusion workflows. AACR reported that, as of June 2025, the FDA had approved 4 BTK inhibitors for non-Hodgkin lymphoma and other hematologic malignancies, which points to a deeper treatment bench in blood cancers. The May 2026 approval of an all-oral AML regimen and the June 2025 approval of a BRUKINSA tablet support home treatment continuity for patients who would otherwise depend more heavily on facility visits. That keeps breast cancer as the largest base today, while blood cancer adds some of the strongest forward momentum in the chemotherapy at home services industry.

Geography Analysis

North America accounted for 45.64% of revenue in 2025 in the chemotherapy at home services market, and that lead rests on a combination of scale operators, payer support, and value-based oncology policy. Option Care Health reported more than 190 locations, more than 5,000 clinicians, and service across all 50 U.S. states, which illustrates the network depth available in the region. CMS also strengthened the operating backdrop through the Enhancing Oncology Model, which increased Monthly Enhanced Oncology Services payments and supported more patient-centered oncology workflows. The chemotherapy at home services market share in North America is also supported by stronger administrative ability to manage authorization, compounding, dispatch, and compliance at scale.

Europe remains the second-largest regional cluster in the chemotherapy at home services market, but growth is less uniform than in North America. Progress is strongest where hospital oncology teams, homecare providers, and public payment systems already work through linked operating pathways. At the same time, a peer-reviewed Belgian study showed that oncology treatment at home can cost more than standard hospital care when reimbursement is not designed to cover operating reality. That gap slows expansion because clinical feasibility alone does not guarantee provider investment or routine program scale.

Asia-Pacific is forecast to grow at a 9.59% CAGR through 2031 in the chemotherapy at home services market, making it the fastest-growing regional block. The region has a large untreated opportunity because cancer volumes are high and hospital capacity remains uneven across urban and non-urban settings. Growth is strongest where digital coordination, urban nurse availability, and payer openness are improving at the same time. South Korea and Australia already have established home infusion provider networks, while other countries are moving through earlier stages of structured oncology-at-home development. South America and the Middle East and Africa remain smaller in revenue terms, but the chemotherapy at home services market is gaining relevance there as health systems search for more flexible ways to deliver treatment outside major hospitals.